Evropská unie - chorvatština - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - ibandroninska kiselina - osteoporoza, postmenopauzalna - lijekovi za liječenje bolesti kostiju - liječenje osteoporoze kod žena u postmenopauzi s povećanim rizikom od prijeloma (vidi odjeljak 5. smanjenje rizika od prijeloma kralježaka je pokazao učinkovitost na prijeloma vrata bedrene kosti nije instaliran.

Evropská unie - chorvatština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - imunosupresivi - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Evropská unie - chorvatština - EMA (European Medicines Agency)

teva b.v. - Триоксид arsen - leukemija, promyelocytic, akutna - antineoplastična sredstva - Тризенокс prikazan za indukciju remisije i konsolidacije kod odraslih pacijenata s je prvi put dijagnosticiran niski i srednji rizik od akutne промиелоцитарной leukemije (ОПЛ) (bijelih krvnih stanica ≤ 10 x 103/Μl) u kombinaciji s potpuno trans‑ретиноевая kiselina (ПТРК)relapsed/тугоплавким oštar промиелоцитарный leukemije (ОПЛ) (prethodni tretman treba da sadrže retinoid i kemoterapije), karakterizira t(15;17) translokacije i/ili dostupnost, ili za pro-myelocytic Лейков/ретиноевая-kiselina-receptor alfa (od pml/rar-alfa) gena. brzina reakcije druge akutne mijeloične podtipovi leukemije do триоксида arsen ne smatra.

Evropská unie - chorvatština - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, бримонидин tartarat - ocular hypertension; glaucoma, open-angle - ophthalmologicals - smanjenje povišenog intraokularnog tlaka (iop) u odraslih bolesnika s otvorenim kutnim glaukom ili očne hipertenzije za koje monoterapija osigurava nedovoljnu redukciju iop.

Evropská unie - chorvatština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudin - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - tvrdi capsuleszerit je navedeno u kombinaciji s drugim антиретровирусными lijekovima za liječenje hiv-inficiranih odraslih pacijenata i pedijatrijska bolesnika (u dobi od tri mjeseca) samo onda, kada ostali lijekovi ne mogu se koristiti. trajanje terapije s zerit treba ograničiti u najkraćem mogućem roku. prašak za oralni solutionzerit prikazan u kombinaciji s drugim антиретровирусными lijekovima za liječenje hiv-inficiranih odraslih pacijenata i pedijatrijska bolesnika (od rođenja) samo onda, kada ostali lijekovi ne mogu se koristiti. trajanje terapije s zerit treba ograničiti u najkraćem mogućem roku.

Evropská unie - chorvatština - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, эмтрицитабин, Тенофовир alafenamide, фумарат - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (vidi odjeljak 5.

Evropská unie - chorvatština - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropská unie - chorvatština - EMA (European Medicines Agency)

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Evropská unie - chorvatština - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - Клопидогрел prikazan odrasle za prevenciju атеротромботических događaja:pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija. patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. za više informacija, molimo pogledajte odjeljak 5.

Evropská unie - chorvatština - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin i линаглиптин - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - glyxambi, fiksnih doza kombinacija empagliflozin i i линаглиптин, pojavljuje se kod odraslih u dobi od 18 godina i stariji sa dijabetesom tip 2:za poboljšanje glikemijski kontrole pri метформина i/ili sulfonilureje (su) i jedan od однокомпонентных od glyxambi ne pružaju adekvatnu glikemijski kontrole;kad već лечусь iz slobodne kombinacije линаглиптин empagliflozin i i.